Comment to “Telaprevir Experience From Turkey”

Authors Information
Article Notes and Dates
To Cite : Akar T, Malkoc D, Aydemir S. Comment to “Telaprevir Experience From Turkey”, Hepat Mon. 2015 ;15(11):e58820. doi: 10.5812/hepatmon.29821.
Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
  • 1. Komur S, Kurtaran B, Inal AS, Pullukcu H, Ulu A, Kuscu F, et al. Telaprevir experience from Turkey. Hepat Mon. 2015; 15(2)[DOI][PubMed]
  • 2. European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60(2): 392-420[DOI][PubMed]
  • 3. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013; 59(3): 434-41[DOI][PubMed]
  • 4. Akar T. Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhi. ACG Case Reports J. 2015; 2(2): 79[DOI]
  • 5. Rodriguez-Medina B, Blanes M, Vinaixa C, Aguilera V, Rubin A, Prieto M, et al. Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. Ann Hepatol. 2013; 12(6): 974-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check